The Philanthropy of Eric Lefkofsky Serves Diverse Organizations

Recent statistics have shown a worrying trend in the spread of cancer in the United States. In 2014, there were roughly 14.5 million Americans diagnosed with cancer. Tempus has been one of the companies spearheading revolutionary advances that try to make effective cancer treatment.

Tempus, a leading tech company in data-enabled precision medicine was founded by Eric Lefkofsky after he went through the treatment process with a loved one who was diagnosed. He came to realize just how undeveloped the technology infrastructure was in healthcare.

When Tempus launched, it set up a lofty but impressive goal. The goal was to revolutionize cancer treatment through big data and analytics. The company designed a platform to be used in the analysis of a patient’s molecular and clinical data.

It is worth noting that the efforts and contribution made by Tempus to the effective treatment of cancer are for the purposes of improving life and ensuring every cancer patient is given an equal opportunity of quality cancer care. For instance, when we consider molecular data, this is simply genomic transformation collected via sequencing of human genome. This has is a practice which was very expensive back in 2003 when first mapping of human genome took place. The costs of preforming this process stood at a whooping $100 million. However, much appreciation goes to the numerous advances in science and technology which have brought these prohibitive costs of genome mapping down exponentially.

One might want to know why the success of Tempus in promoting the sequencing of human genome is crucial. The answer is quite simple: to open up secrets on how to effectively combat chronic killer diseases such as cancer. We have observed that most researchers on cancer usually focus on combating the cancer menace at the molecular and cellular levels. There are plentiful cues in the human genes which can shade light on multiple ways of effectively fighting killer diseases including cancer. Tempus and its CEO, Eric Lefkofsky, are building the world’s largest database of molecular and clinical data and an operating system that will make that data useful for physicians and the patients they are treating. With every piece of data added to the system, paired and compared with the existing data and researchers could then analyze the same to unlock secrets that could prove monumental in combating cancer and similar diseases.

Eric and his colleagues in data-enabled precision medicine believe the time is now to bring data-driven treatment to cancer. Equipped with data and technology, doctors will better be able to identify which treatments and medicines are likely to work on the patient and which ones are likely to fail. The continuous update and availability of the molecular and clinical data is aimed at assisting doctors to come up with real-time decisions with regards to treating cancer patients as well as patients suffering from a host of other deadly diseases.

Eric Lefkofsky was born in September 1969, Southfield Michigan. He graduated with high honors from the University of Michigan and later got a Juris Doctor from the University of Michigan Law School. Although he studied law, Eric Lefkofsky realized in college that he was suited to life as an entrepreneur.

Lefkofsky, a native of Michigan, has spent most of his life in Chicago where Tempus is headquartered. As a member of the board of directors at the Art Institute of Chicago, Lurie's Children’s Memorial Hospital and chairman of Board of Trustees at Chicago’s Steppenwolf Theatre Company, Lefkofsky has held various teaching positions throughout the years as well. He currently works as an adjunct professor at the Booth School of Business at the University of Chicago.